These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 10649997)

  • 1. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
    Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
    Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
    Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
    J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.
    Reinke R; Lee DJ; Robinson WE
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3301-3. PubMed ID: 12234866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.
    King PJ; Lee DJ; Reinke RA; Victoria JG; Beale K; Robinson WE
    Virology; 2003 Feb; 306(1):147-61. PubMed ID: 12620807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
    Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
    J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.
    Espeseth AS; Felock P; Wolfe A; Witmer M; Grobler J; Anthony N; Egbertson M; Melamed JY; Young S; Hamill T; Cole JL; Hazuda DJ
    Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11244-9. PubMed ID: 11016953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore.
    Kehlenbeck S; Betz U; Birkmann A; Fast B; Göller AH; Henninger K; Lowinger T; Marrero D; Paessens A; Paulsen D; Pevzner V; Schohe-Loop R; Tsujishita H; Welker R; Kreuter J; Rübsamen-Waigmann H; Dittmer F
    J Virol; 2006 Jul; 80(14):6883-94. PubMed ID: 16809294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.
    Pluymers W; Pais G; Van Maele B; Pannecouque C; Fikkert V; Burke TR; De Clercq E; Witvrouw M; Neamati N; Debyser Z
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3292-7. PubMed ID: 12234864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.
    Zahm JA; Bera S; Pandey KK; Vora A; Stillmock K; Hazuda D; Grandgenett DP
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3358-68. PubMed ID: 18591263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.
    Hazuda DJ; Anthony NJ; Gomez RP; Jolly SM; Wai JS; Zhuang L; Fisher TE; Embrey M; Guare JP; Egbertson MS; Vacca JP; Huff JR; Felock PJ; Witmer MV; Stillmock KA; Danovich R; Grobler J; Miller MD; Espeseth AS; Jin L; Chen IW; Lin JH; Kassahun K; Ellis JD; Wong BK; Xu W; Pearson PG; Schleif WA; Cortese R; Emini E; Summa V; Holloway MK; Young SD
    Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11233-8. PubMed ID: 15277684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully flexible low-mode docking: application to induced fit in HIV integrase.
    Keserû GM; Kolossváry I
    J Am Chem Soc; 2001 Dec; 123(50):12708-9. PubMed ID: 11741448
    [No Abstract]   [Full Text] [Related]  

  • 13. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.
    Robinson WE; Cordeiro M; Abdel-Malek S; Jia Q; Chow SA; Reinecke MG; Mitchell WM
    Mol Pharmacol; 1996 Oct; 50(4):846-55. PubMed ID: 8863829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H.
    Corona A; di Leva FS; Rigogliuso G; Pescatori L; Madia VN; Subra F; Delelis O; Esposito F; Cadeddu M; Costi R; Cosconati S; Novellino E; di Santo R; Tramontano E
    Antiviral Res; 2016 Oct; 134():236-243. PubMed ID: 27659398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
    Maurin C; Bailly F; Cotelle P
    Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells.
    Balakrishnan M; Yant SR; Tsai L; O'Sullivan C; Bam RA; Tsai A; Niedziela-Majka A; Stray KM; Sakowicz R; Cihlar T
    PLoS One; 2013; 8(9):e74163. PubMed ID: 24040198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
    Kobayashi M; Yoshinaga T; Seki T; Wakasa-Morimoto C; Brown KW; Ferris R; Foster SA; Hazen RJ; Miki S; Suyama-Kagitani A; Kawauchi-Miki S; Taishi T; Kawasuji T; Johns BA; Underwood MR; Garvey EP; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2011 Feb; 55(2):813-21. PubMed ID: 21115794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.
    Vandegraaff N; Kumar R; Hocking H; Burke TR; Mills J; Rhodes D; Burrell CJ; Li P
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2510-6. PubMed ID: 11502522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
    Johnson AA; Marchand C; Pommier Y
    Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical screening assays to identify HIV-1 integrase inhibitors.
    Clynhens M; Smets A; Vereycken I; Van Loock M; Clayton R; Meersseman G; Goethals O
    Methods Mol Biol; 2013; 1030():25-36. PubMed ID: 23821258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.